SOLV // Solventum Corporation

DES <GO> NYSE CIK 0001964738 ↗

Health Care • Medical/Dental Instruments

$83.56 ▲ +1.71 (+2.09%)

MKT CAP: $14.22B • VOL: 1.09M

52W L $62 52W H $94

ALTMAN Z

2.25 GREY

PIOTROSKI

6 / 9

SOLV // ROARABLE RATING & 5-PILLAR RQD CONFIDENCE 02:00 EST DETERMINISTIC ENGINE

PRIOR: RQD 59/100 [C-] (+0 PT) • UNCHANGED AS OF 2026-11-01

ROARABLE C-

RQD CONFIDENCE

59 / 100 +0D

5 X 20-PT QUANT PILLARS

E 0 D 35 C 59 B 70 A 86+

Roarable Hold — Cautious Neutral

01 MASSIVE / SEC XBRL

Forensic Fundamentals

[LOCKED] FLAGGED

UNLOCK BELOW TO REVEAL

02 OPRA GEX + SEC 13F

Whale & Options Flow

10 / 20

NEUTRAL

NET GEX +0% • CALL SWEEP 52% • P/C 0.81

03 SEC FORM 4 (90D)

Insider Conviction

[LOCKED] FLAGGED

UNLOCK BELOW TO REVEAL

04 FRED 90D r-MATRIX

Macro Regime Fit

16 / 20

STRONG

TAILWIND • r(10Y)=+0.00 (+23bp) • r(OAS)=+0.00

05 10-K REDLINE AUDIT

Forensic 10-K Risk

13 / 20

SOLID

20 BASE - 7 DEDUCT • 0 CRIT / 0 MED • STABLE

ALERT

Why did SOLV's Forensic Fundamentals & Insider Conviction sub-score just flash a warning? Enter your email to unlock the full 5-Pillar Rating Breakdown + get instant alerts whenever SOLV is Upgraded or Downgraded.

SIG <GO> CROSS-FEED TRIANGULATION // PROPRIETARY ANOMALY ENGINE (1 ACTIVE ON SOLV)

STAGE 2 DETERMINISTIC Z-SCORE + STAGE 3 GEEK DESK BRIEF ALL MARKET ANOMALIES <SIG>

▼ BEARISH // F-RATED EARNINGS MIRAGE // ACCRUAL WATCHSIFTER 02 // ACCRUAL & RECEIVABLES FORENSICS

SEVERITY: 94/100 Z-SCORE: +4.95σ

SOLV Accounting Gap: Net Income (+220%) Outpaced OCF (-68.9%) With +19% Working-Capital Build

CASH CONVERSION GAP

+288.9% (NI vs OCF)

RECEIVABLES / WC BLOAT

+19.0% VS REV

60D C-SUITE FORM 4 SALES

0 OPEN-MKT DUMPS

[GEEK DESK FORENSIC NOTE // SEC XBRL × FORM 4 CROSS-CHECK]

SEC EDGAR XBRL CompanyFacts10-K/10-Q Working Capital ScheduleSEC Form 4 Executive Sales

SEC EDGAR XBRL triangulation on Solventum Corporation (SOLV) exposes a +288.9% Cash Conversion Gap as YoY Net Income growth (+220.0%) diverged from Operating Cash Flow growth (-68.9%). Non-cash current assets and receivables expanded +19.0% relative to top-line revenue growth. Monitor upcoming 10-Q cash realization closely for accrual mean-reversion.

SOLV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +20.74%▼ SUPPORT BREAKDOWN

2026-10-30O $84.15H $84.48L $80.76C $81.33VOL 1.07M

RES: $87.78SUP: $83.88SMA50: $88.09SMA200: $78.37

SOLV // INSTITUTIONAL BULL VS. BEAR FORENSIC DEBATE

NEUTRAL / PAIR TRADE CONVICTION: 52/100

BEAR 0

100 BULL

Solventum Corporation (SOLV) exhibits 53.5% gross margins and 18.7% return on invested capital within Health Care (Medical/Dental Instruments), balanced against a 7.3x enterprise multiple and 7.1% implied options volatility.

▲ INSTITUTIONAL BULL THESIS (LONG)

01. Operating Leverage & Capital Efficiency Moat

Sustained 53.5% gross profitability converts into 26.2% operating margin and 18.7% ROIC, outpacing sector cost of capital.

ROIC: 18.7% // GM: 53.5%

02. Top-Line Expansion & Cash Conversion

YoY revenue trajectory of +0.9% paired with -0.07% free cash flow yield supports self-funded R&D and capital return.

REV YOY: +0.9% // FCF YLD: -0.07%

03. Balance Sheet Solvency & Forensic Quality

Altman Z-Score of 2.25 and Piotroski F-Score of 6/9 indicate low near-term refinancing stress.

ALTMAN Z: 2.25 // F-SCORE: 6/9

▼ INSTITUTIONAL BEAR THESIS (SHORT / RISK)

01. Multiple Compression & Duration Sensitivity

Trading at 9.1x trailing P/E (8.5x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.

P/E: 9.1x // EV/EBITDA: 7.3x

02. Options Skew & Event Volatility Risk

Options market prices a ±7.1% implied move with a 0.81 put/call ratio around $82.00 max pain.

IMPL MOVE: ±7.1% // P/C: 0.81

03. Competitive Margin & CapEx Cycle Pressure

Elevated industry capital intensity and customer concentration in Medical/Dental Instruments require continuous execution to defend 18.7% net margins.

NET MARGIN: 18.7% // D/E: 1.00x

KEY CATALYST // Upcoming 10-Q/10-K XBRL margin progression, guidance revision vs 8.5x forward consensus, and institutional 13F positioning.

MACRO REGIME // Monitor US 10Y Real Yields (DFII10) and High-Yield Credit Spreads (OAS) for beta-adjusted multiple impact (Beta 1.06).

FORM 4 & 13F FLOW OPEN OWN <GO>

FILER	SIDE	$ VALUE
INSPECT FULL OWNERSHIP LEDGER IN OWN <GO>

UNUSUAL OPTIONS TAPE OPEN OPT <GO>

STRIKE / EXP	TYPE	PREMIUM
INSPECT GEX & CHAIN IN OPT <GO>

KEY VALUATION & PROFITABILITY RATIOS XBRL FA <GO>

TRAILING P/E 9.1x

FORWARD P/E 8.5x

EV / EBITDA 7.3x

FCF YIELD -0.07%

GROSS MARGIN 53.5%

OPERATING MARGIN 26.2%

NET MARGIN 18.7%

ROIC % 18.7%

REV GROWTH YOY +0.9%

DILUTED EPS TTM $9.14

DEBT / EQUITY 1.00x

DIVIDEND YIELD 0.00%

RSI-14 MOMENTUM 35.3

5Y EQUITY BETA 1.06

FRED MACRO SENSITIVITY (PEARSON r) ECST <GO>

MACRO CORRELATION CALIBRATION ACTIVE BELOW.

FRED MACRO REGIME STRESS-TEST SIMULATOR // SOLVPEARSON R VARIANCE ENGINE

01 // SELECT FEDERAL RESERVE & CREDIT SHOCK SCENARIO

02 // POSITION NOTIONAL EXPOSURE

HEADLINE STRESS SCORE

75/100SEVERE DRAWDOWN PRESSURE

PRIMARY FACTOR EXPOSURE

DFII10 // -0.61 r

Latest: 2.08%

EST. DIRECTIONAL MOVE

-8.50%

Implied Px: $76.46

EST. DOLLAR VARIANCE

-$4,248

On $50,000 Notional

[LOCKED // MULTI-FACTOR DRAWDOWN HEDGE & MACRO TRIGGER ALERT]

Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for SOLV & activate live FRED threshold breach alerts.

HEAD-TO-HEAD PEER COMPARISONS COMP <GO>

SOLV VS LLY

MARGINS ROIC VALUATION

SOLV VS JNJ

MARGINS ROIC VALUATION

SOLV VS ABBV

MARGINS ROIC VALUATION

SOLV VS UNH

MARGINS ROIC VALUATION